Medical/Pharmaceuticals

Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients

- New research published in Clinical Cancer Research shows significant improvement in distant recurrence-free survival with combined durvalumab and tremelimumab treatment, supported by Lunit SCOPE IO's analysis of tumor microenvironment SEOUL, South Korea, March 26, 2024 /PRNewswire/ -- Lunit (K...

2024-03-26 21:00 532

TiumBio Submits CTA for Phase 1b Clinical Trial of TU7710, a Long-acting Recombinant Activated Factor VII, in Hemophilia A or B Patients

* TU7710 has the potential to be a highly effective and long-acting treatment for bleeding episodes as well as for preventing bleeding during surgery or invasive procedures in hemophilia patients with inhibitors * Interim results from an ongoing Phase 1a study in healthy male volunteers will ...

2024-03-26 20:00 525

Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa

* MCO-010 achieved its primary and key secondary endpoints with statistical significance and no serious adverse events * Data from the Phase 2b RESTORE trial demonstrate clinically meaningful vision improvement in legally blind individuals with progressive and permanent neurodegeneration of t...

2024-03-26 19:00 681

Alphamab Oncology Announces the First Patient Dosed in Australia in the Clinical Study of Subcutaneous Formulation JSKN033

SUZHOU, China, March 26, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been dosed inAustralia in the clinical study (JSKN033-101) of JSKN033, a subcutaneous formulation with HER2 bispecific antibody-conjugated drug and PD-L1 monoclonal antibody,...

2024-03-26 09:57 909

Scivita Medical Expands Collaboration with Boston Scientific

SUZHOU, China, March 26, 2024 /PRNewswire/ -- Recently, Scivita Medical Technology Co., Ltd. ("Scivita Medical") and Boston Scientific Corporation (NYSE: BSX), a leading global medical technology company, joined hands again to sign an expanded strategic cooperation arrangement.

2024-03-26 09:30 1008

BioDuro-Sundia's Partner, DigmBio Announced IND Clearance from Korea MFDS for its Selective PARP1 Inhibitor DM5167

SHANGHAI, March 26, 2024 /PRNewswire/ -- BioDuro-Sundia's partner, DigmBio, a South Korean biotechnology company, announced its selective PARP1 inhibitor for the treatment of triple-negative breast cancer has been approved by Korea Food and Drug Administration (MFDS) for Investigational New Drug ...

2024-03-26 08:30 898

Full-Life Technologies Achieves Regulatory Milestone with Nuclear Permit, Advancing Radioisotope Facility Construction

GEMBLOUX, Belgium, March 25, 2024 /PRNewswire/ -- Full-Life Technologies ("Full-Life"), today announced the recent achievement of its subsidiary "Full-Life Technology Europe" has obtained a Nuclear Permit for a class IIA facility from the Belgium Federal Agency for Nuclear Control ("FANC"), auth...

2024-03-26 08:00 656

Mom Favorite Brand Momcozy Showcases Cutting-Edge Products at Medtrade 2024

NEW YORK, March 25, 2024 /PRNewswire/ -- Medtrade 2024 attendees looking for mom-centric products now have a new option on the Expo Floor,Momcozy . The mom-oriented, global brand is dedicated to provid...

2024-03-25 23:00 889

Yunkang Announces 2023 Annual Results, Revenue Reaches RMB892 Million

Steps up R&D investment Focuses on precision medicine and intelligent testing sectors HONG KONG, March 25, 2024 /PRNewswire/ -- Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its annual results for the year...

2024-03-25 22:54 1424

GenieMD Awarded Frost & Sullivan's 2024 Company of the Year Award for Pioneering Virtual Chronic Disease Management Solutions Through Its Unified Virtual Care Platform

GenieMD offers a comprehensive virtual care platform, integrating telehealth, remote patient monitoring, chronic care management, and AI-driven insights to impact the treatment and management of chronic diseases. SAN ANTONIO, March 25, 2024 /PRNewswire/ -- Frost & Sullivan recently researched th...

2024-03-25 22:31 1153

WuXi XDC Delivers Outstanding Performance in 2023 with over 110% Year-On-Year Growth for Both Revenue and Adjusted Net Profit and Achieves Significant Corporate Milestones

* Revenue reached RMB 2,124 million, an increase of 114% compared with Year 2022 * Adjusted net profit reached RMB 412 million, an increase of 112% compared with Year 2022 * Total number of integrated projects increased to 143 * 50 new integrated projects signed in 2023 * Number of Phase...

2024-03-25 21:39 1701

GC Genome to Present New Data at AACR 2024

Offering Hope for Enhanced Early Detection and Patient Care in the Battle Against Cancer YONGIN, South Korea, March 25, 2024 /PRNewswire/ -- GC Genome Corporation, a leading diagnostics company, today announced that the company will present two poster presentations at the American Association fo...

2024-03-25 21:00 1126

Sirtex Medical Appoints Matt Schmidt as New Chief Executive Officer and Board of Directors Member

WOBURN, Mass., March 25, 2024 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional treatment solutions, announced today the appointment ofMatt Schmidt as chief executive officer and board of directors member, effectiveMarch 25. Since joining Sirtex in 2023, Schmidt...

2024-03-25 20:00 1108

ANNOUNCEMENT OF 2023 ANNUAL RESULTS OF TONG REN TANG TECHNOLOGIES

BEIJING, March 25, 2024 /PRNewswire/ -- Tong Ren Tang Technologies Co. Ltd. (" Tong Ren Tang Technologies" or the "Group", 1666.HK) is pleased to announce the audited consolidated results of the Group for the year ended31 December 2023. In 2023, the Group's revenue amounted to RMB6.77 billion, rep...

2024-03-25 12:47 1698

New PeerLINC Knowledge Hub will Leverage Local Expertise and Experience to Accelerate New, More Effective TB Cures Around the World

Hub will focus on supporting global use of new treatments that effectively treated drug-resistant TB in 98% of Filipino participants MANILA, Australia, March 25, 2024 /PRNewswire/ -- TB Alliance's new Peer-to-Peer Learning for Innovative Cures (PeerLINC) Knowledge Hub launched today inManila, wi...

2024-03-25 10:00 634

Australian Government Grants TB Alliance an Award to Help Bolster Clinical Research and Improve Access to New Treatments for Drug-Resistant TB

AUD 17 Million Grant over 5 Years Will Fund Next-Generation TB Cures CANBERRA, Australia, March 25, 2024 /PRNewswire/ -- The Australian Government, through the Partnerships for a Healthy Region initiative, has announced a new AUD 17 million grant to support work with TB Alliance through its Pro...

2024-03-25 08:04 567

Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results

Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy Integrating R&D, manufacturing and commercial upsides by acquiring full intellectual property rights of BRII-179 and expanding it...

2024-03-22 19:00 3220

The Results of Phase II Clinical Study of KN046 Plus Chemotherapy as First-line Treatment for Metastatic NSCLC were Published in Cell Reports Medicine

SUZHOU, China, March 22, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the phase II clinical research results of anti- PD-L1/CTLA-4 bispecific antibody KN046 plus chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC) were published o...

2024-03-22 18:42 2357

Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress Across First-in-Class, Best-in-Class Pipeline

* Promising clinical activities and efficacies during dose escalations for four lead global rights programs targeting CD24, Claudin 18.2, CD73, and PD-L1/4-1BB * Positive, differentiated cervical cancer data advancing mTORC1/2 inhibitor on registrational track for APAC markets * RMB1.188 bi...

2024-03-22 18:00 4794
12345 ... 572

Week's Top Stories